Intica Neo 7 DR-T DF-1 ProMRI, Intica Neo 5 DR-T DF-1 ProMRI
Biotronik, Inc. · Decision date Oct 13, 2026
What did the FDA decide?
The FDA record shows a 30-day notice for P000009/S134 from Biotronik, Inc., filed under the product code MRM for an implantable dual-chamber defibrillator. The stated change concerns the rework process for manufacturing the housing of pulse generators and ICDs. The supplement reason is listed as a process change involving manufacturer, sterilizer, packager, or supplier; the database does not specify which of these roles apply or which site is affected.
The P000009 identifier ties the notice to the original PMA, but a supplement is not a new approval of the whole system, and this manufacturing notice is not an original PMA. The source statement reports the purpose of the change only; it provides no data demonstrating safety or clinical effectiveness, and no conclusions about either should be drawn from the decision code alone. Missing from the record are the specific rework steps, the housing materials, validation results, and the scope of devices affected.
FDA approval order statement
a change to the rework process for the manufacturing of the housing for pulse generators and ICDS
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 13, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P000009/S134
- Regulatory pathway
- PMA supplement
- Applicant
- Biotronik, Inc.
- Product code
- MRM
- Decision code
- OK30
- Decision date
- Oct 13, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: DEFIBRILLATOR, IMPLANTABLE, DUAL-CHAMBER.
- Applicant
- Biotronik, Inc.
- Product code
- MRM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P000009. Subsequent supplements may change the device or its indications.
FDA decision timeline
P000009 · Original PMA
PHYLAX AV ICD SYSTEM
P000009/S130 · Related supplement
PSW 2601.U, NEO 2601.U, Acticor Sky DR-T, Rivacor Sky DR-T, Rivacor Rise DR-T, Rivacor Aura DR-T
P000009/S134 received
Application receipt date recorded by FDA.
P000009/S124 · Related supplement
Ilivia Neo 7 DR-T 429529; Intica Neo 7 DR-T 429558; Intica Neo 5 DR-T 429568
P000009/S133 · Related supplement
Acticor Sky DR-T, Rivacor Sky DR-T, Rivacor Rise DR-T, Rivacor Aura DR-T, Acticor 7 DR-T, Rivacor 7 DR-T, Rivacor 5 DR-T
P000009/S132 · Related supplement
Acticor Sky DR-T 481987; Rivacor Sky DR-T 481982; Rivacor Rise DR-T 482018; Rivacor Aura DR-T 482014
P000009/S134 · FDA decision
30-Day Notice
P000009/S128 · Related supplement
BIOexpress
P000009/S135 · Related supplement
Ilivia Neo 7 DRT, Intica Neo 7 DRT, Intica Neo 5 DRT, Acticor Sky DR-T, Rivacor Sky DR-T, Rivacor Rise DR-T, Rivacor Aur
Timeline entries are records held by MedtechLedger for P000009. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P000009
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PHYLAX AV ICD SYSTEMP000009 | Biotronik, Inc. | PMA approval | Sep 29, 2000 | FDA |
| Biotronik, Inc. | PMA supplement | Sep 17, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
BIOexpressP000009/S128 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA |
Explore the linked device profile
Other records with product code MRM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
BIOexpressP050023/S209 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6024 Jean Rd., Lake Oswego, OR, 97035
Sources and methodology
- Original FDA record: P000009/S134
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




